It is therefore pivotal to confirm these findings in a prospective study and investigate TP53 mutation status in routine clinical practice for cases of MYC translocation positive DLBCL, in addition to the current standard investigation for BCL2 translocation. This evidence concerns the gene MYC and diffuse large B-cell lymphoma.